News >

Cemiplimab Antitumor Activity in CSCC Sustained With Longer Follow-up

Kristi Rosa
Published: Monday, Dec 17, 2018

Taofeek Owonikoko MD, PhD

Taofeek Owonikoko MD, PhD

The monoclonal anti-PD-1 antibody cemiplimab (Libtayo) continued to demonstrate considerable antitumor activity and durable responses in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), according to follow-up data from a phase I trial presented at the 2018 ESMO Congress.1

Across the entire population of this combined analysis, the overall response rate (ORR) at a median follow-up of 8.9 months was 47% (95% CI, 38%-47%).2 The complete response (CR) rate was 4% and the partial response (PR) rate was 44%, and the duration of response (DOR) ranged from 1 month to over 15 months. Moreover, 61% of patients had a DOR ≥6 months.

Although the disease has a surgical cure rate upwards of 95%, there are an estimated 3932 to 8791 disease-related deaths in the United States in 2012.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20202.0
Publication Bottom Border
Border Publication